US6018026A
(en)
|
1988-01-22 |
2000-01-25 |
Zymogenetics, Inc. |
Biologically active dimerized and multimerized polypeptide fusions
|
US5567584A
(en)
*
|
1988-01-22 |
1996-10-22 |
Zymogenetics, Inc. |
Methods of using biologically active dimerized polypeptide fusions to detect PDGF
|
US5750375A
(en)
*
|
1988-01-22 |
1998-05-12 |
Zymogenetics, Inc. |
Methods of producing secreted receptor analogs and biologically active dimerized polypeptide fusions
|
EP0325224B1
(en)
*
|
1988-01-22 |
1996-07-31 |
ZymoGenetics, Inc. |
Methods of producing secreted receptor analogs
|
EP0345466A3
(en)
*
|
1988-05-10 |
1991-04-17 |
EASTMAN KODAK COMPANY (a New Jersey corporation) |
Generation of chimeric antibodies in vivo by site-specific recombination
|
US6780613B1
(en)
|
1988-10-28 |
2004-08-24 |
Genentech, Inc. |
Growth hormone variants
|
CA2345497A1
(en)
|
1988-10-28 |
1990-04-28 |
Genentech, Inc. |
Growth hormone variants and method for forming growth hormone variants
|
DE3909799A1
(de)
*
|
1989-03-24 |
1990-09-27 |
Behringwerke Ag |
Monoklonale antikoerper (mak) gegen tumorassoziierte antigene, ihre herstellung und verwendung
|
ATE236249T1
(de)
|
1989-09-12 |
2003-04-15 |
Hoffmann La Roche |
Tfn-bindende proteine
|
CA2066720A1
(en)
*
|
1989-09-19 |
1991-03-20 |
David M. Knight |
Method for improving human monoclonal antibody production
|
US6713610B1
(en)
*
|
1990-01-12 |
2004-03-30 |
Raju Kucherlapati |
Human antibodies derived from immunized xenomice
|
US6075181A
(en)
*
|
1990-01-12 |
2000-06-13 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
US6657103B1
(en)
*
|
1990-01-12 |
2003-12-02 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
WO1991010741A1
(en)
*
|
1990-01-12 |
1991-07-25 |
Cell Genesys, Inc. |
Generation of xenogeneic antibodies
|
US6150584A
(en)
*
|
1990-01-12 |
2000-11-21 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
US6673986B1
(en)
*
|
1990-01-12 |
2004-01-06 |
Abgenix, Inc. |
Generation of xenogeneic antibodies
|
US5633425A
(en)
*
|
1990-08-29 |
1997-05-27 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
US5625126A
(en)
*
|
1990-08-29 |
1997-04-29 |
Genpharm International, Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
US7041871B1
(en)
*
|
1995-10-10 |
2006-05-09 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
US6300129B1
(en)
|
1990-08-29 |
2001-10-09 |
Genpharm International |
Transgenic non-human animals for producing heterologous antibodies
|
US5874299A
(en)
*
|
1990-08-29 |
1999-02-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
US5661016A
(en)
*
|
1990-08-29 |
1997-08-26 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
US7084260B1
(en)
*
|
1996-10-10 |
2006-08-01 |
Genpharm International, Inc. |
High affinity human antibodies and human antibodies against human antigens
|
US5770429A
(en)
*
|
1990-08-29 |
1998-06-23 |
Genpharm International, Inc. |
Transgenic non-human animals capable of producing heterologous antibodies
|
EP0546073B1
(en)
*
|
1990-08-29 |
1997-09-10 |
GenPharm International, Inc. |
production and use of transgenic non-human animals capable of producing heterologous antibodies
|
US5877397A
(en)
*
|
1990-08-29 |
1999-03-02 |
Genpharm International Inc. |
Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
|
US5814318A
(en)
*
|
1990-08-29 |
1998-09-29 |
Genpharm International Inc. |
Transgenic non-human animals for producing heterologous antibodies
|
US5545806A
(en)
*
|
1990-08-29 |
1996-08-13 |
Genpharm International, Inc. |
Ransgenic non-human animals for producing heterologous antibodies
|
US7405270B2
(en)
|
1991-10-25 |
2008-07-29 |
Immunex Corporation |
CD40-Ligand lacking native-pattern glycosylation
|
US5981724A
(en)
|
1991-10-25 |
1999-11-09 |
Immunex Corporation |
DNA encoding CD40 ligand, a cytokine that binds CD40
|
US5962406A
(en)
*
|
1991-10-25 |
1999-10-05 |
Immunex Corporation |
Recombinant soluble CD40 ligand polypeptide and pharmaceutical composition containing the same
|
US5961974A
(en)
|
1991-10-25 |
1999-10-05 |
Immunex Corporation |
Monoclonal antibodies to CD40 ligand, pharmaceutical composition comprising the same and hybridomas producing the same
|
ATE175998T1
(de)
*
|
1992-03-10 |
1999-02-15 |
Jolla Cancer Res Found |
Rekombinierte alkalische phosphatase aus kälberdarm
|
US5736137A
(en)
*
|
1992-11-13 |
1998-04-07 |
Idec Pharmaceuticals Corporation |
Therapeutic application of chimeric and radiolabeled antibodies to human B lymphocyte restricted differentiation antigen for treatment of B cell lymphoma
|
KR100463476B1
(ko)
*
|
1993-12-23 |
2005-07-01 |
머크 앤드 캄파니 인코포레이티드 |
쥐과의동물세포들을위한상동성재조합항체발현시스템
|
GB2299336A
(en)
*
|
1993-12-23 |
1996-10-02 |
Merck & Co Inc |
Homologous recombination antibody expression sysstem for murine cells
|
CA2182498A1
(en)
|
1994-02-01 |
1995-08-10 |
William J. Larochelle |
Fusion proteins that include antibody and nonantibody portions
|
US5541110A
(en)
|
1994-05-17 |
1996-07-30 |
Bristol-Myers Squibb |
Cloning and expression of a gene encoding bryodin 1 from Bryonia dioica
|
CA2219486A1
(en)
*
|
1995-04-28 |
1996-10-31 |
Abgenix, Inc. |
Human antibodies derived from immunized xenomice
|
CZ299025B6
(cs)
|
1996-02-09 |
2008-04-02 |
Amgen Inc. |
Farmaceutická kompozice a její použití
|
KR20080059467A
(ko)
*
|
1996-12-03 |
2008-06-27 |
아브게닉스, 인크. |
복수의 vh 및 vk 부위를 함유하는 사람 면역글로불린유전자좌를 갖는 형질전환된 포유류 및 이로부터 생성된항체
|
ES2312179T3
(es)
|
1996-12-06 |
2009-02-16 |
Amgen Inc. |
Terapia combinada que utiliza un inhibidor del il-1 para el tratamiento de enfermedades mediadas por el il-1.
|
CA2279231C
(en)
|
1997-02-07 |
2013-11-26 |
The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services |
Activity dependent neurotrophic factor iii (adnf iii)
|
ATE314395T1
(de)
|
1997-04-07 |
2006-01-15 |
Genentech Inc |
Humanisierte antikörper und verfahren zu ihrer herstellung
|
EP1787999B1
(en)
|
1997-04-07 |
2010-08-04 |
Genentech, Inc. |
Anti-VEGF antibodies
|
US6391547B1
(en)
*
|
1997-09-09 |
2002-05-21 |
Center For The Application Of Molecular Biology To International Agriculture |
Microbial β-glucuronidase genes, gene products and uses thereof
|
US7087420B1
(en)
|
1997-07-17 |
2006-08-08 |
Cambia |
Microbial β-glucuronidase genes, gene products and uses thereof
|
CA2307016A1
(en)
*
|
1997-10-24 |
1999-05-06 |
Life Technologies, Inc. |
Recombinational cloning using nucleic acids having recombination sites
|
US6528624B1
(en)
*
|
1998-04-02 |
2003-03-04 |
Genentech, Inc. |
Polypeptide variants
|
BR0008758A
(pt)
*
|
1999-01-15 |
2001-12-04 |
Genentech Inc |
Variantes de polipeptìdeos parentais com funçãoefetora alterada, polipeptìdeos, composição ácidonucleico isolado, vetor, célula hospedeira,método para produzir uma variante depolipeptìdeo, método para o tratamento de umadesordem em mamìferos e método para produziruma região fc variante
|
US7183387B1
(en)
|
1999-01-15 |
2007-02-27 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
US6737056B1
(en)
*
|
1999-01-15 |
2004-05-18 |
Genentech, Inc. |
Polypeptide variants with altered effector function
|
US6911429B2
(en)
*
|
1999-04-01 |
2005-06-28 |
Transition Therapeutics Inc. |
Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
|
US6864235B1
(en)
|
1999-04-01 |
2005-03-08 |
Eva A. Turley |
Compositions and methods for treating cellular response to injury and other proliferating cell disorders regulated by hyaladherin and hyaluronans
|
WO2001094413A2
(en)
|
2000-06-06 |
2001-12-13 |
Bristol-Myers Squibb Company |
B7-related nucleic acids and polypeptides and their uses for immunomodulation
|
EA013564B1
(ru)
*
|
2000-08-03 |
2010-06-30 |
Терапеутик Хьюман Поликлоналз Инк. |
Гуманизированный иммуноглобулин и содержащая его фармацевтическая композиция
|
EP1916303B1
(en)
*
|
2000-11-30 |
2013-02-27 |
Medarex, Inc. |
Nucleic acids encoding rearranged human immunoglobulin sequences from transgenic transchromosomal mice
|
AU2002309063B8
(en)
*
|
2001-05-11 |
2008-04-24 |
Kyowa Kirin Co., Ltd. |
Artificial human chromosome containing human antibody lambda light chain gene
|
US20030157108A1
(en)
*
|
2001-10-25 |
2003-08-21 |
Genentech, Inc. |
Glycoprotein compositions
|
WO2003040368A2
(en)
*
|
2001-11-09 |
2003-05-15 |
Transition Therapeutics Inc. |
Pharmaceutical compositions of marine sponge microciona prolifera
|
US7332585B2
(en)
|
2002-04-05 |
2008-02-19 |
The Regents Of The California University |
Bispecific single chain Fv antibody molecules and methods of use thereof
|
AU2003304411A1
(en)
|
2002-08-01 |
2005-03-07 |
The Regents Of The University Of California |
Therapeutic monoclonal antibodies that neutralize botulinum neurotoxins
|
US7282568B2
(en)
|
2002-12-16 |
2007-10-16 |
Medarex, Inc. |
Human monoclonal antibodies against interleukin 8 (IL-8)
|
AR045614A1
(es)
*
|
2003-09-10 |
2005-11-02 |
Hoffmann La Roche |
Anticuerpos contra el recepctor de la interleuquina- 1 y los usos de los mismos
|
AU2005222947B2
(en)
|
2004-03-16 |
2010-12-23 |
Onconova Therapeutics Inc. |
Substituted phenoxy- and phenylthio- derivatives for treating proliferative disorders
|
WO2005095458A1
(en)
*
|
2004-04-02 |
2005-10-13 |
The Talwar Research Foundation |
CHIMERIC MONOCLONAL ANTIBODY FOR BINDING WITH HIGH AFFINITY SELECTIVELY TO hCG
|
US7794713B2
(en)
*
|
2004-04-07 |
2010-09-14 |
Lpath, Inc. |
Compositions and methods for the treatment and prevention of hyperproliferative diseases
|
SG172616A1
(en)
|
2004-04-13 |
2011-07-28 |
Hoffmann La Roche |
Anti-p-selectin antibodies
|
TWI380996B
(zh)
|
2004-09-17 |
2013-01-01 |
Hoffmann La Roche |
抗ox40l抗體
|
DK1797127T3
(en)
|
2004-09-24 |
2017-10-02 |
Amgen Inc |
Modified Fc molecules
|
EP2433647A3
(en)
|
2005-01-27 |
2012-06-06 |
Children's Hospital & Research Center at Oakland |
GNA1870-based vesicle vaccines for broad spectrum protection against diseases caused by Neisseria meningitidis
|
JP2008528060A
(ja)
|
2005-01-27 |
2008-07-31 |
ザ リージェンツ オブ ザ ユニバーシティ オブ カリフォルニア |
ボツリヌス神経毒素を中和する治療的モノクローナル抗体
|
TW200720289A
(en)
|
2005-04-01 |
2007-06-01 |
Hoffmann La Roche |
Antibodies against CCR5 and uses thereof
|
US8008453B2
(en)
|
2005-08-12 |
2011-08-30 |
Amgen Inc. |
Modified Fc molecules
|
NZ594784A
(en)
*
|
2005-08-18 |
2013-06-28 |
Genmab As |
Therapy with CD4 binding peptides and radiation
|
US20090074720A1
(en)
*
|
2005-10-28 |
2009-03-19 |
Sabbadini Roger A |
Methods for decreasing immune response and treating immune conditions
|
US20080213274A1
(en)
*
|
2005-10-28 |
2008-09-04 |
Sabbadini Roger A |
Compositions and methods for the treatment and prevention of fibrotic, inflammatory, and neovascularization conditions of the eye
|
AU2007235496B2
(en)
*
|
2006-03-31 |
2013-11-21 |
E. R. Squibb & Sons, L.L.C. |
Transgenic animals expressing chimeric antibodies for use in preparing human antibodies
|
US7846724B2
(en)
*
|
2006-04-11 |
2010-12-07 |
Hoffmann-La Roche Inc. |
Method for selecting CHO cell for production of glycosylated antibodies
|
US20080014203A1
(en)
*
|
2006-04-11 |
2008-01-17 |
Silke Hansen |
Antibodies against insulin-like growth factor I receptor and uses thereof
|
US7862812B2
(en)
*
|
2006-05-31 |
2011-01-04 |
Lpath, Inc. |
Methods for decreasing immune response and treating immune conditions
|
TW200817438A
(en)
*
|
2006-08-17 |
2008-04-16 |
Hoffmann La Roche |
A conjugate of an antibody against CCR5 and an antifusogenic peptide
|
AU2007286451A1
(en)
|
2006-08-17 |
2008-02-21 |
F. Hoffmann-La Roche Ag |
A conjugate of an antibody against CCR5 and an antifusogenic peptide
|
WO2008027986A2
(en)
|
2006-09-01 |
2008-03-06 |
Therapeutic Human Polyclonals, Inc. |
Enhanced expression of human or humanized immunoglobulin in non-human transgenic animals
|
JP4960459B2
(ja)
|
2006-09-29 |
2012-06-27 |
エフ.ホフマン−ラ ロシュ アーゲー |
Ccr5に対する抗体およびその使用
|
US7833527B2
(en)
|
2006-10-02 |
2010-11-16 |
Amgen Inc. |
Methods of treating psoriasis using IL-17 Receptor A antibodies
|
US7829674B2
(en)
|
2006-10-27 |
2010-11-09 |
Lpath, Inc. |
Compositions and methods for binding sphingosine-1-phosphate
|
EP2083862A4
(en)
*
|
2006-10-27 |
2012-09-19 |
Lpath Inc |
COMPOSITIONS AND METHODS FOR TREATING OCULAR DISEASES AND DISORDERS
|
US20080226635A1
(en)
*
|
2006-12-22 |
2008-09-18 |
Hans Koll |
Antibodies against insulin-like growth factor I receptor and uses thereof
|
US9163091B2
(en)
*
|
2007-05-30 |
2015-10-20 |
Lpath, Inc. |
Compositions and methods for binding lysophosphatidic acid
|
DK2164992T3
(en)
*
|
2007-05-30 |
2016-08-15 |
Lpath Inc |
COMPOSITIONS AND METHODS FOR BONDING OF LYTHOPHOSPHATIC ACID
|
ES2665920T3
(es)
*
|
2007-06-29 |
2018-04-30 |
F. Hoffmann-La Roche Ag |
Mutante de cadena pesada para mejorar la producción de inmunoglobulina
|
US20090022720A1
(en)
*
|
2007-07-20 |
2009-01-22 |
Stephan Fischer |
Conjugate of an antibody against CD4 and antifusogenic peptides
|
AU2008295140A1
(en)
|
2007-09-05 |
2009-03-12 |
F. Hoffmann-La Roche Ag |
Combination therapy with type I and type II anti-CD20 antibodies
|
WO2009039192A2
(en)
|
2007-09-17 |
2009-03-26 |
The Regents Of The University Of Californina |
Internalizing human monoclonal antibodies targeting prostate cancer cells in situ
|
BRPI0818165B8
(pt)
|
2007-10-12 |
2021-05-25 |
Hoffmann La Roche |
método de produção recombinante de uma imunoglobulina heteróloga em células cho que é secretada para o meio de cultura
|
US20090098118A1
(en)
|
2007-10-15 |
2009-04-16 |
Thomas Friess |
Combination therapy of a type ii anti-cd20 antibody with an anti-bcl-2 active agent
|
US8361465B2
(en)
*
|
2007-10-26 |
2013-01-29 |
Lpath, Inc. |
Use of anti-sphingosine-1-phosphate antibodies in combination with chemotherapeutic agents
|
JP5221673B2
(ja)
|
2007-12-15 |
2013-06-26 |
エフ.ホフマン−ラ ロシュ アーゲー |
識別アッセイ
|
US9266967B2
(en)
|
2007-12-21 |
2016-02-23 |
Hoffmann-La Roche, Inc. |
Bivalent, bispecific antibodies
|
US20090162359A1
(en)
|
2007-12-21 |
2009-06-25 |
Christian Klein |
Bivalent, bispecific antibodies
|
US8227577B2
(en)
*
|
2007-12-21 |
2012-07-24 |
Hoffman-La Roche Inc. |
Bivalent, bispecific antibodies
|
JP5570998B2
(ja)
|
2007-12-31 |
2014-08-13 |
バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング |
TNFαに対する抗体
|
JP6018361B2
(ja)
|
2008-01-31 |
2016-11-02 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
制御性t細胞活性を抑制するための、ヒトcd39に対する抗体およびその使用
|
US20100255508A1
(en)
|
2008-05-16 |
2010-10-07 |
Thomas Richard Gelzleichter |
Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists
|
US8790642B2
(en)
|
2008-08-29 |
2014-07-29 |
Genentech, Inc. |
Cross-reactive and bispecific anti-IL-17A/F antibodies
|
DK2346994T3
(da)
|
2008-09-30 |
2022-02-28 |
Ablexis Llc |
Knock-in-mus til fremstilling af kimære antistoffer
|
EP2355847A1
(en)
|
2008-10-07 |
2011-08-17 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Neutralizing antibodies and fragments thereof directed against platelet factor-4 variant 1 (pf4v1)
|
US8268314B2
(en)
|
2008-10-08 |
2012-09-18 |
Hoffmann-La Roche Inc. |
Bispecific anti-VEGF/anti-ANG-2 antibodies
|
US8871202B2
(en)
|
2008-10-24 |
2014-10-28 |
Lpath, Inc. |
Prevention and treatment of pain using antibodies to sphingosine-1-phosphate
|
WO2010069858A1
(en)
*
|
2008-12-19 |
2010-06-24 |
F. Hoffmann-La Roche Ag |
Pharmaceutical composition
|
US9399670B2
(en)
|
2009-02-20 |
2016-07-26 |
Hoffmann-La Roche Inc. |
Method for obtaining immunoglobulin encoding nucleic acid
|
WO2010106051A1
(en)
|
2009-03-17 |
2010-09-23 |
Universite De La Mediterranee |
Btla antibodies and uses thereof
|
WO2010115728A2
(en)
|
2009-03-30 |
2010-10-14 |
F. Hoffmann-La Roche Ag |
A method for avoiding glass fogging
|
EP2236139A1
(en)
|
2009-03-31 |
2010-10-06 |
F. Hoffmann-La Roche AG |
Combination therapy of erlotinib with an anti-IGF-1R antibody, which does not inhibit binding of insulin to the insulin receptor
|
US20100247484A1
(en)
|
2009-03-31 |
2010-09-30 |
Heinrich Barchet |
Combination therapy of an afucosylated antibody and one or more of the cytokines gm csf, m csf and/or il3
|
WO2010112194A1
(en)
|
2009-04-02 |
2010-10-07 |
F. Hoffmann-La Roche Ag |
Antigen-binding polypeptides and multispecific antibodies comprising them
|
JP5501439B2
(ja)
*
|
2009-04-02 |
2014-05-21 |
ロシュ グリクアート アクチェンゲゼルシャフト |
完全長抗体と単鎖Fabフラグメントとを含む多重特異的抗体
|
US8093006B2
(en)
|
2009-04-02 |
2012-01-10 |
Hoffmann-La Roche Inc. |
Antibodies against human tweak and uses thereof
|
AU2010233993A1
(en)
|
2009-04-07 |
2011-09-08 |
Roche Glycart Ag |
Bispecific anti-ErbB-1/anti-c-Met antibodies
|
KR20110124369A
(ko)
|
2009-04-07 |
2011-11-16 |
로슈 글리카트 아게 |
이중특이적 항erbb3/항cmet 항체
|
SG175077A1
(en)
|
2009-04-07 |
2011-11-28 |
Roche Glycart Ag |
Trivalent, bispecific antibodies
|
AU2010252284A1
(en)
|
2009-05-27 |
2011-11-17 |
F. Hoffmann-La Roche Ag |
Tri- or tetraspecific antibodies
|
US9676845B2
(en)
|
2009-06-16 |
2017-06-13 |
Hoffmann-La Roche, Inc. |
Bispecific antigen binding proteins
|
ES2536996T3
(es)
|
2009-07-06 |
2015-06-01 |
F. Hoffmann-La Roche Ag |
Anticuerpos biespecíficos de unión a digoxigenina
|
SG177764A1
(en)
|
2009-07-30 |
2012-03-29 |
Hoffmann La Roche |
Enzymatic antibody processing
|
CN102471383B
(zh)
|
2009-08-04 |
2014-09-17 |
霍夫曼-拉罗奇有限公司 |
β细胞标记抗体
|
WO2011019620A1
(en)
|
2009-08-10 |
2011-02-17 |
Genentech, Inc. |
Antibodies with enhanced adcc function
|
US20110053223A1
(en)
|
2009-08-14 |
2011-03-03 |
Robert Bayer |
Cell culture methods to make antibodies with enhanced adcc function
|
TWI409079B
(zh)
|
2009-08-14 |
2013-09-21 |
Roche Glycart Ag |
非典型岩藻醣化cd20抗體與苯達莫斯汀(bendamustine)之組合療法
|
BR112012003066A2
(pt)
|
2009-08-14 |
2016-11-16 |
Roche Glycart Ag |
uso de um anticorpo anti-cd20 defucosilado e composição compreendendo um anticorpo anti-cd20 defucosilado
|
TW201113037A
(en)
|
2009-08-28 |
2011-04-16 |
Hoffmann La Roche |
Antibodies against CDCP1 for the treatment of cancer
|
TWI412375B
(zh)
|
2009-08-28 |
2013-10-21 |
Roche Glycart Ag |
人類化抗cdcp1抗體
|
EP2289542A1
(en)
|
2009-08-31 |
2011-03-02 |
PAION Deutschland GmbH |
Treatment of neurological or neurodegenerative disorders
|
BR112012002249A2
(pt)
|
2009-09-07 |
2016-06-14 |
Hoffmann La Roche |
método para determinação da glicosilação de uma imunoglobulina e uso de um método
|
AR078161A1
(es)
|
2009-09-11 |
2011-10-19 |
Hoffmann La Roche |
Formulaciones farmaceuticas muy concentradas de un anticuerpo anti cd20. uso de la formulacion. metodo de tratamiento.
|
MX2012003396A
(es)
|
2009-09-16 |
2012-04-10 |
Genentech Inc |
Complejos de proteina conteniendo helice super-enrollada y/o enlazador tether y usos de los mismos.
|
DK2483310T3
(da)
|
2009-09-29 |
2014-09-01 |
Roche Glycart Ag |
Bispecifik dødsreceptor-agonistiske antistoffer
|
TW201117824A
(en)
|
2009-10-12 |
2011-06-01 |
Amgen Inc |
Use of IL-17 receptor a antigen binding proteins
|
EP2491397B1
(en)
|
2009-10-19 |
2017-04-19 |
F. Hoffmann-La Roche AG |
NON-CROSS-REACTIVE ANTI IgG ANTIBODIES
|
EP4406615A2
(en)
|
2009-10-26 |
2024-07-31 |
F. Hoffmann-La Roche AG |
Method for the production of a glycosylated immunoglobulin
|
BR112012012213A2
(pt)
|
2009-11-26 |
2017-01-10 |
Hoffmann La Roche |
proteína marcada para diabetes do tipo 2
|
DK2949670T3
(da)
|
2009-12-10 |
2019-05-13 |
Hoffmann La Roche |
Antistoffer, der fortrinsvis binder humant ekstracellulært CSF1R-domæne 4 og anvendelse deraf
|
AU2010335283B2
(en)
|
2009-12-22 |
2016-01-14 |
F. Hoffmann-La Roche Ag |
Sequence dependent aggregation
|
HUE029026T2
(en)
|
2009-12-22 |
2017-01-30 |
Roche Glycart Ag |
Anti-HER3 antibodies and their applications
|
EA031209B9
(ru)
|
2010-01-15 |
2021-11-19 |
Кирин-Эмджен, Инк. |
Фармацевтический состав антитела для лечения воспалительного заболевания и способы его применения
|
US20120294866A1
(en)
|
2010-01-19 |
2012-11-22 |
F. Hoffmann-La Roche Ag |
Pharmaceutical formulation for proteins
|
US20110200595A1
(en)
|
2010-02-18 |
2011-08-18 |
Roche Glycart |
TREATMENT WITH A HUMANIZED IgG CLASS ANTI EGFR ANTIBODY AND AN ANTIBODY AGAINST INSULIN LIKE GROWTH FACTOR 1 RECEPTOR
|
MX2012010014A
(es)
|
2010-03-05 |
2012-09-21 |
Hoffmann La Roche |
Anticuerpos contra csf-1r humano y sus usos.
|
CA2789071C
(en)
|
2010-03-05 |
2018-03-27 |
F. Hoffmann-La Roche Ag |
Antibodies against human csf-1r and uses thereof
|
EP2550285B1
(en)
|
2010-03-22 |
2017-07-19 |
President and Fellows of Harvard College |
Trioxacarcins and uses thereof
|
AR080794A1
(es)
*
|
2010-03-26 |
2012-05-09 |
Hoffmann La Roche |
Anticuerpos bivalentes biespecificos anti- vegf/ anti-ang-2
|
AR080793A1
(es)
|
2010-03-26 |
2012-05-09 |
Roche Glycart Ag |
Anticuerpos biespecificos
|
AU2011234988B2
(en)
|
2010-03-31 |
2014-10-30 |
Ablexis, Llc |
Genetic engineering of non-human animals for the production of chimeric antibodies
|
KR101620661B1
(ko)
|
2010-04-27 |
2016-05-12 |
로슈 글리카트 아게 |
어푸코실화된 CD20 항체와 mTOR 억제제의 복합 요법
|
WO2012010696A1
(en)
|
2010-07-23 |
2012-01-26 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for cancer management targeting co-029
|
RU2603284C2
(ru)
|
2010-08-17 |
2016-11-27 |
Ф.Хоффманн-Ля Рош Аг |
АНТИТЕЛА ПРОТИВ IgG1 ЧЕЛОВЕКА
|
AR082693A1
(es)
|
2010-08-17 |
2012-12-26 |
Roche Glycart Ag |
Terapia de combinacion de un anticuerpo anti-cd20 afucosilado con un anticuerpo anti-vegf
|
JP5758004B2
(ja)
|
2010-08-24 |
2015-08-05 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
ジスルフィドによって安定化されたFv断片を含む二重特異性抗体
|
WO2012027440A1
(en)
|
2010-08-24 |
2012-03-01 |
Abbott Laboratories |
Hiv core protein specific antibodies and uses thereof
|
US9187564B2
(en)
|
2010-10-05 |
2015-11-17 |
Hoffmann-La Roche Inc. |
Antibodies against human TWEAK and uses thereof
|
MX336940B
(es)
|
2010-10-25 |
2016-02-08 |
Hoffmann La Roche |
Uso de compuestos mejoradores de señal en deteccion de electroquimioluminiscencia.
|
WO2012080769A1
(en)
|
2010-12-15 |
2012-06-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Anti-cd277 antibodies and uses thereof
|
RU2013131444A
(ru)
|
2010-12-16 |
2015-01-27 |
Рош Гликарт Аг |
Сочетанная терапия афукозилированным антителом к cd20 и ингибитором mdm2
|
US20140162317A1
(en)
|
2010-12-21 |
2014-06-12 |
Roberto Falkenstein |
Isoform entriched antibody preparation and method for obtaining it
|
DK2654789T3
(en)
|
2010-12-22 |
2018-09-03 |
Orega Biotech |
ANTIBODIES AGAINST HUMAN CD39 AND USE THEREOF
|
WO2012085111A1
(en)
|
2010-12-23 |
2012-06-28 |
F. Hoffmann-La Roche Ag |
Polypeptide-polynucleotide-complex and its use in targeted effector moiety delivery
|
WO2012101125A1
(en)
|
2011-01-24 |
2012-08-02 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Specific antibodies against human cxcl4 and uses thereof
|
WO2012116927A1
(en)
|
2011-02-28 |
2012-09-07 |
F. Hoffmann-La Roche Ag |
Monovalent antigen binding proteins
|
ES2549638T3
(es)
|
2011-02-28 |
2015-10-30 |
F. Hoffmann-La Roche Ag |
Proteínas de unión a antígeno
|
PL3318571T3
(pl)
|
2011-03-16 |
2021-07-05 |
F. Hoffmann-La Roche Ag |
Chromatografia jonowymienna o ulepszonej selektywności do rozdzielania monomerów, agregatów i fragmentów polipeptydowych przez modulację fazy ruchomej
|
AU2012234335B2
(en)
|
2011-03-29 |
2016-09-01 |
Roche Glycart Ag |
Antibody Fc variants
|
MX343623B
(es)
|
2011-03-31 |
2016-11-14 |
Centre Leon Berard |
Anticuerpos dirigidos contra icos y usos de los mismos.
|
KR20130137688A
(ko)
|
2011-03-31 |
2013-12-17 |
제넨테크, 인크. |
베타7 인테그린 길항제를 투여하는 방법
|
AR086250A1
(es)
|
2011-05-05 |
2013-11-27 |
Hoffmann La Roche |
Polipeptido de fusion presentador de una secuencia de aminoacidos y utilizacion del mismo
|
CN103890010B
(zh)
|
2011-05-19 |
2017-04-19 |
法国国家健康医学研究院 |
抗‑人‑her3抗体及其用途
|
RU2013158594A
(ru)
|
2011-06-15 |
2015-07-20 |
Ф. Хоффманн-Ля Рош Аг |
Антитело, связывающееся с полипептидом авса1
|
JP6033293B2
(ja)
|
2011-06-22 |
2016-11-30 |
インサーム(インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル)Inserm(Institut National Dela Sante Et De La Recherche Medicale) |
抗Axl抗体及びその使用
|
JP6120833B2
(ja)
|
2011-06-22 |
2017-04-26 |
インサーム(インスティテュ ナシオナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシェ メディカル)Inserm(Institut National Dela Sante Et De La Recherche Medicale) |
抗Axl抗体及びその使用
|
EP2543679A1
(en)
|
2011-07-08 |
2013-01-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antibodies for the treatment and prevention of thrombosis
|
EP2543677A1
(en)
|
2011-07-08 |
2013-01-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antibodies for the treatment and prevention of thrombosis
|
EP2543678A1
(en)
|
2011-07-08 |
2013-01-09 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antibodies for the treatment and prevention of thrombosis
|
WO2013016220A1
(en)
|
2011-07-22 |
2013-01-31 |
Amgen Inc. |
Il-17 receptor a is required for il-17c biology
|
EP2747781B1
(en)
|
2011-08-23 |
2017-11-15 |
Roche Glycart AG |
Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
|
RU2617970C2
(ru)
|
2011-08-23 |
2017-04-28 |
Рош Гликарт Аг |
Антитела, не содержащие fc-фрагмента, включающие два fab-фрагмента, и способы их применения
|
UA115657C2
(uk)
|
2011-09-19 |
2017-12-11 |
Аксон Ньюросайєнс Сє |
Виділене антитіло, яке зв'язується з одним або декількома епітопами тау, фармацевтична композиція, що його містить, спосіб лікування та спосіб діагностики хвороби альцгеймера на основі виділеного антитіла
|
MX2014003326A
(es)
|
2011-09-21 |
2014-04-25 |
Hoffmann La Roche |
Metodo para obtener fragmentos de fab a partir de celulas unicas productoras de un anticuerpo mediante pcr multiplexado en combinacion con sondas taqman.
|
CN104302668A
(zh)
|
2011-09-23 |
2015-01-21 |
罗氏格黎卡特股份公司 |
双特异性的抗-egfr/抗igf-1r抗体
|
JP5854535B2
(ja)
|
2011-10-05 |
2016-02-09 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
抗体g1グリコフォーム産生のための方法
|
US20130302274A1
(en)
|
2011-11-25 |
2013-11-14 |
Roche Glycart Ag |
Combination therapy
|
RU2658603C2
(ru)
|
2011-12-15 |
2018-06-21 |
Ф.Хоффманн-Ля Рош Аг |
Антитела против человеческого csf-1r и их применения
|
FR2984750B1
(fr)
|
2011-12-23 |
2014-01-10 |
Lfb Biotechnologies |
Nouvelles compositions pharmaceutiques comprenant un anticorps liant le recepteur humain de l'hormone anti-mullerienne de type ii
|
WO2013119966A2
(en)
|
2012-02-10 |
2013-08-15 |
Genentech, Inc. |
Single-chain antibodies and other heteromultimers
|
CN104136460A
(zh)
|
2012-02-29 |
2014-11-05 |
霍夫曼-拉罗奇有限公司 |
减少1->3读框移位的方法
|
WO2013127700A1
(en)
|
2012-02-29 |
2013-09-06 |
F. Hoffmann-La Roche Ag |
Method for reduction of 1->2 reading frame shifts
|
AR090244A1
(es)
|
2012-03-08 |
2014-10-29 |
Hoffmann La Roche |
Formulacion de anticuerpo anti-selectina p
|
AR090263A1
(es)
|
2012-03-08 |
2014-10-29 |
Hoffmann La Roche |
Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma
|
AU2013229613B2
(en)
|
2012-03-08 |
2015-07-30 |
F. Hoffmann-La Roche Ag |
Abeta antibody formulation
|
EA201401077A1
(ru)
|
2012-04-05 |
2015-02-27 |
Ф.Хоффманн-Ля Рош Аг |
Биспецифические антитела к человеческому tweak и человеческому il17 и их применения
|
EP2666786A1
(en)
|
2012-05-21 |
2013-11-27 |
PAION Deutschland GmbH |
Immunotherapy for intracranial hemorrhage
|
CN104379604A
(zh)
|
2012-05-24 |
2015-02-25 |
弗·哈夫曼-拉罗切有限公司 |
多特异性抗体
|
HUE043552T2
(hu)
|
2012-06-08 |
2019-09-30 |
Sutro Biopharma Inc |
Antitestek, amelyek tartalmaznak helyspecifikus nem természetes aminosav maradékokat, eljárások elõállításukra és eljárások használatukra
|
EP2864355B1
(en)
|
2012-06-25 |
2016-10-12 |
Orega Biotech |
Il-17 antagonist antibodies
|
EP2867253B1
(en)
|
2012-06-27 |
2016-09-14 |
F. Hoffmann-La Roche AG |
Method for selection and production of tailor-made highly selective and multi-specific targeting entities containing at least two different binding entities and uses thereof
|
JP6309002B2
(ja)
|
2012-06-27 |
2018-04-11 |
エフ.ホフマン−ラ ロシュ アーゲーF. Hoffmann−La Roche Aktiengesellschaft |
標的に特異的に結合する少なくとも1つの結合実体を含む抗体Fc領域結合体を作製するための方法およびその使用
|
EP2684896A1
(en)
|
2012-07-09 |
2014-01-15 |
International-Drug-Development-Biotech |
Anti-DR5 family antibodies, bispecific or multivalent anti-DR5 family antibodies and methods of use thereof
|
ES2690312T3
(es)
|
2012-07-13 |
2018-11-20 |
Roche Glycart Ag |
Anticuerpos biespecíficos anti-VEGF/anti-ANG-2 y su uso en el tratamiento de enfermedades vasculares oculares
|
US9695247B2
(en)
|
2012-09-03 |
2017-07-04 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Antibodies directed against ICOS for treating graft-versus-host disease
|
RU2648476C2
(ru)
|
2012-09-07 |
2018-03-26 |
Дженентек, Инк. |
Комбинированная терапия с использованием антитела против cd20 типа ii и селективного ингибитора bcl-2
|
AR092908A1
(es)
|
2012-10-05 |
2015-05-06 |
Genentech Inc |
Metodos para diagnosticar y tratar enfermedad intestinal inflamatoria
|
WO2014056783A1
(en)
|
2012-10-08 |
2014-04-17 |
Roche Glycart Ag |
Fc-free antibodies comprising two fab-fragments and methods of use
|
EP2727943A1
(en)
|
2012-11-05 |
2014-05-07 |
MAB Discovery GmbH |
Trispecific antibodies against human EGFR, HER2 and HER3
|
EP2727942A1
(en)
|
2012-11-05 |
2014-05-07 |
MAB Discovery GmbH |
Bispecific antibodies against human EGFR, HER2, and HER3
|
EP2914629A1
(en)
|
2012-11-05 |
2015-09-09 |
MAB Discovery GmbH |
Method for the production of multispecific antibodies
|
EP2727941A1
(en)
|
2012-11-05 |
2014-05-07 |
MAB Discovery GmbH |
Method for the production of multispecific antibodies
|
EP2733153A1
(en)
|
2012-11-15 |
2014-05-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for the preparation of immunoconjugates and uses thereof
|
DK3199552T3
(da)
|
2012-11-20 |
2020-03-30 |
Sanofi Sa |
Anti-ceacam5-antistoffer og anvendelser heraf
|
JP6408478B2
(ja)
|
2012-11-26 |
2018-10-17 |
プレジデント アンド フェローズ オブ ハーバード カレッジ |
トリオキサカルシン、トリオキサカルシン−抗体複合体、およびその用途
|
EP2931293B1
(en)
|
2012-12-12 |
2019-02-20 |
University Of Virginia Patent Foundation |
Compositions and methods for regulating erythropoiesis
|
EP3514175A1
(fr)
|
2012-12-17 |
2019-07-24 |
Laboratoire Français du Fractionnement et des Biotechnologies |
Utilisation d'anticorps monoclonaux pour le traitement de l'inflammation et d'infections bacteriennes
|
SG11201504920SA
(en)
|
2012-12-27 |
2015-07-30 |
Sanofi Sa |
Anti-lamp1 antibodies and antibody drug conjugates, and uses thereof
|
AR094403A1
(es)
|
2013-01-11 |
2015-07-29 |
Hoffmann La Roche |
Terapia de combinación de anticuerpos anti-her3
|
EP2953974B1
(en)
|
2013-02-05 |
2017-12-20 |
EngMab Sàrl |
Bispecific antibodies against cd3epsilon and bcma
|
EP2762497A1
(en)
|
2013-02-05 |
2014-08-06 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
EP2762496A1
(en)
|
2013-02-05 |
2014-08-06 |
EngMab AG |
Method for the selection of antibodies against BCMA
|
EP3495814A3
(en)
|
2013-03-27 |
2019-07-17 |
F. Hoffmann-La Roche AG |
Use of biomarkers for assessing treatment of gastrointestinal inflammatory disorders with beta7 integrin antagonists
|
WO2014161570A1
(en)
|
2013-04-03 |
2014-10-09 |
Roche Glycart Ag |
Antibodies against human il17 and uses thereof
|
UA118028C2
(uk)
|
2013-04-03 |
2018-11-12 |
Рош Глікарт Аг |
Біспецифічне антитіло, специфічне щодо fap і dr5, антитіло, специфічне щодо dr5, і спосіб їх застосування
|
EP2789630A1
(en)
|
2013-04-09 |
2014-10-15 |
EngMab AG |
Bispecific antibodies against CD3e and ROR1
|
AR095882A1
(es)
|
2013-04-22 |
2015-11-18 |
Hoffmann La Roche |
Terapia de combinación de anticuerpos contra csf-1r humano con un agonista de tlr9
|
US10005839B2
(en)
|
2013-05-17 |
2018-06-26 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Antagonist of the BTLA/HVEM interaction for use in therapy
|
EP3019522B1
(en)
|
2013-07-10 |
2017-12-13 |
Sutro Biopharma, Inc. |
Antibodies comprising multiple site-specific non-natural amino acid residues, methods of their preparation and methods of their use
|
WO2015014979A1
(en)
|
2013-08-01 |
2015-02-05 |
F. Hoffmann-La Roche Ag |
Tnfa-il-17 bispecific antibodies
|
EP2832854A1
(en)
|
2013-08-02 |
2015-02-04 |
F. Hoffmann-La Roche AG |
Method for improving the recombinant expression of a polypeptide by C-terminal fusion to human neprilysin
|
AR097584A1
(es)
|
2013-09-12 |
2016-03-23 |
Hoffmann La Roche |
Terapia de combinación de anticuerpos contra el csf-1r humano y anticuerpos contra el pd-l1 humano
|
MX2016003593A
(es)
|
2013-10-11 |
2016-06-02 |
Hoffmann La Roche |
Anticuerpos de cadena ligera variable comun intercambiada de dominio multiespecifico.
|
WO2015067986A1
(en)
|
2013-11-07 |
2015-05-14 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Neuregulin allosteric anti-her3 antibody
|
WO2015082446A1
(en)
|
2013-12-02 |
2015-06-11 |
F. Hoffmann-La Roche Ag |
Treatment of cancer using an anti-cdcp1 antibody and a taxane
|
BR112016020053A2
(pt)
|
2014-03-27 |
2018-02-20 |
Genentech, Inc. |
métodos de previsão da reação de pacientes que sofrem de distúrbio inflamatório, de previsão da capacidade de reação de pacientes, de identificação de pacientes que sofrem de distúrbio inflamatório e de seu tratamento, usos de kit e kits
|
US20170174772A1
(en)
|
2014-03-31 |
2017-06-22 |
Kirin-Amgen, Inc. |
Methods of treating nail and scalp psoriasis
|
UA117289C2
(uk)
|
2014-04-02 |
2018-07-10 |
Ф. Хоффманн-Ля Рош Аг |
Мультиспецифічне антитіло
|
US10544231B2
(en)
|
2014-04-16 |
2020-01-28 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antibodies for the prevention or the treatment of bleeding episodes
|
FR3020063A1
(fr)
|
2014-04-16 |
2015-10-23 |
Gamamabs Pharma |
Anticorps humain anti-her4
|
EP3172233B1
(en)
|
2014-07-22 |
2019-09-11 |
Sutro Biopharma, Inc. |
Anti-cd74 antibodies, compositions comprising anti-cd74 antibodies and methods of using anti-cd74 antibodies
|
JP6692343B2
(ja)
|
2014-08-01 |
2020-05-13 |
アンスティチュ ナショナル ドゥ ラ サンテ エ ドゥ ラ ルシェルシュ メディカル |
薬物としての使用のための抗cd45rc抗体
|
EP2982692A1
(en)
|
2014-08-04 |
2016-02-10 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
EP3204415B1
(en)
|
2014-10-09 |
2020-06-17 |
EngMab Sàrl |
Bispecific antibodies against cd3epsilon and ror1
|
WO2016059220A1
(en)
|
2014-10-16 |
2016-04-21 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Tcr-activating agents for use in the treatment of t-all
|
HUE053239T2
(hu)
|
2014-11-19 |
2021-06-28 |
Axon Neuroscience Se |
Humanizált tau-ellenanyagok Alzheimer-kór kezelésére
|
EP3023437A1
(en)
|
2014-11-20 |
2016-05-25 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA
|
HUE059632T2
(hu)
|
2014-11-20 |
2022-12-28 |
Hoffmann La Roche |
T-sejteket aktiváló bispecifikus antigénkötõ molekulák és PD-1 tengelyt célzó antagonisták kombinációs terápiája
|
PL3227332T3
(pl)
|
2014-12-03 |
2020-06-15 |
F. Hoffmann-La Roche Ag |
Wielospecyficzne przeciwciała
|
EP3029068A1
(en)
|
2014-12-03 |
2016-06-08 |
EngMab AG |
Bispecific antibodies against CD3epsilon and BCMA for use in the treatment of diseases
|
TN2017000275A1
(en)
|
2015-01-23 |
2018-10-19 |
Sanofi Sa |
Anti-cd3 antibodies, anti-cd123 antibodies and bispecific antibodies specifically binding to cd3 and/or cd123
|
CN113209289A
(zh)
|
2015-02-26 |
2021-08-06 |
豪夫迈·罗氏有限公司 |
治疗Crohn病的整联蛋白β7拮抗剂和方法
|
US20180071413A1
(en)
|
2015-04-07 |
2018-03-15 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Non-invasive imaging of tumor pd-l1 expression
|
EP3091033A1
(en)
|
2015-05-06 |
2016-11-09 |
Gamamabs Pharma |
Anti-human-her3 antibodies and uses thereof
|
EP3314255B1
(en)
|
2015-06-25 |
2019-07-31 |
H. Hoffnabb-La Roche Ag |
Cell based assay for determining antibody or ligand binding and function
|
US10906971B2
(en)
|
2015-06-26 |
2021-02-02 |
Sanofi Biotechnology SAS |
Monoclonal anti-IL-1RAcP antibodies
|
WO2017005847A1
(en)
|
2015-07-07 |
2017-01-12 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Antibodies having specificity to myosin 18a and uses thereof
|
CN107922504B
(zh)
|
2015-07-07 |
2021-07-30 |
豪夫迈·罗氏有限公司 |
抗HER2抗体-药物缀合物和Bcl-2抑制剂的组合疗法
|
PL3328886T3
(pl)
|
2015-07-29 |
2021-02-08 |
Allergan, Inc. |
Przeciwciała ang-2 o wyłącznie ciężkim łańcuchu
|
EP3331910B1
(en)
|
2015-08-03 |
2019-12-11 |
EngMab Sàrl |
Monoclonal antibodies against human b cell maturation antigen (bcma)
|
US10509035B2
(en)
|
2015-08-07 |
2019-12-17 |
Gamamabs Pharma Sa |
Antibodies, antibody drug conjugates and methods of use
|
CA2992788A1
(en)
|
2015-08-14 |
2017-02-23 |
Allergan, Inc. |
Heavy chain only antibodies to pdgf
|
SG10201913366QA
(en)
|
2015-09-17 |
2020-02-27 |
Histide Ag |
Pharmaceutical association for converting a neoplastic cell into a non-neoplastic cell and uses thereof
|
JP7145503B2
(ja)
|
2015-09-17 |
2022-10-03 |
ヒスタイド アクツィエンゲゼルシャフト |
腫瘍細胞を非腫瘍細胞に変換するための医薬的連合体及びその使用
|
WO2017060397A1
(en)
|
2015-10-09 |
2017-04-13 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods for predicting the survival time of subjects suffering from melanoma metastases
|
US20170114127A1
(en)
|
2015-10-22 |
2017-04-27 |
Massachusetts Institute Of Technology |
Vegf-a-binding proteins and her2-binding proteins with enhanced stability against aggregation
|
WO2017087901A2
(en)
|
2015-11-19 |
2017-05-26 |
Sutro Biopharma, Inc. |
Anti-lag3 antibodies, compositions comprising anti-lag3 antibodies and methods of making and using anti-lag3 antibodies
|
WO2017095823A1
(en)
|
2015-11-30 |
2017-06-08 |
The Regents Of The University Of California |
Tumor-specific payload delivery and immune activation using a human antibody targeting a highly specific tumor cell surface antigen
|
BR112018012374A2
(pt)
|
2015-12-16 |
2018-12-04 |
Gritstone Oncology, Inc. |
identificação, fabricação e uso de neoantígeno
|
JP7306827B2
(ja)
|
2016-01-27 |
2023-07-11 |
ストロ バイオファーマ インコーポレーテッド |
抗cd74抗体コンジュゲート、抗cd74抗体コンジュゲートを含む組成物および抗cd74抗体コンジュゲートを使用する方法
|
CA3013333A1
(en)
|
2016-02-26 |
2017-08-31 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Antibodies having specificity for btla and uses thereof
|
WO2017148879A1
(en)
|
2016-03-01 |
2017-09-08 |
F. Hoffmann-La Roche Ag |
Obinutuzumab and rituximab variants having reduced adcp
|
ES2974284T3
(es)
|
2016-03-11 |
2024-06-26 |
Roche Diagnostics Gmbh |
Aminas de cadena ramificada en la detección de electroquimioluminiscencia
|
EP3241845A1
(en)
|
2016-05-06 |
2017-11-08 |
MAB Discovery GmbH |
Humanized anti-il-1r3 antibodies
|
EP3472197A1
(en)
|
2016-06-15 |
2019-04-24 |
Sutro Biopharma, Inc. |
Antibodies with engineered ch2 domains, compositions thereof and methods of using the same
|
TWI790206B
(zh)
|
2016-07-18 |
2023-01-21 |
法商賽諾菲公司 |
特異性結合至cd3和cd123的雙特異性抗體樣結合蛋白
|
CN109661406A
(zh)
|
2016-07-29 |
2019-04-19 |
国家医疗保健研究所 |
靶向肿瘤相关巨噬细胞的抗体及其用途
|
WO2018036852A1
(en)
|
2016-08-25 |
2018-03-01 |
F. Hoffmann-La Roche Ag |
Intermittent dosing of an anti-csf-1r antibody in combination with macrophage activating agent
|
WO2018049261A1
(en)
|
2016-09-09 |
2018-03-15 |
Icellhealth Consulting Llc |
Oncolytic virus expressing immune checkpoint modulators
|
WO2018071597A1
(en)
|
2016-10-12 |
2018-04-19 |
Sutro Biopharma, Inc. |
Anti-folate receptor antibodies, compositions comprising anti-folate receptor antibodies and methods of making and using anti-folate receptor antibodies
|
TW202300515A
(zh)
|
2016-10-20 |
2023-01-01 |
法商賽諾菲公司 |
抗chikv抗體及其用途
|
IL266424B2
(en)
|
2016-11-02 |
2023-09-01 |
Engmab Sarl |
A bispecific antibody against bcma and cd3 and an immunological drug for combined treatment in multiple myeloma
|
US10316037B1
(en)
|
2016-11-04 |
2019-06-11 |
Yale University |
Compounds and methods for treating cancer
|
WO2018089829A1
(en)
|
2016-11-10 |
2018-05-17 |
Fortis Therapeutics, Inc. |
Cd46-specific effector cells and uses thereof
|
JOP20190100A1
(ar)
|
2016-11-19 |
2019-05-01 |
Potenza Therapeutics Inc |
بروتينات ربط مولد ضد مضاد لـ gitr وطرق استخدامها
|
US11773163B2
(en)
|
2016-11-21 |
2023-10-03 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the prophylactic treatment of metastases
|
AU2017367695A1
(en)
|
2016-12-02 |
2019-06-13 |
Juno Therapeutics, Inc. |
Engineered B cells and related compositions and methods
|
JP7141407B2
(ja)
|
2016-12-13 |
2022-09-22 |
エフ.ホフマン-ラ ロシュ アーゲー |
腫瘍試料における標的抗原の存在を決定する方法
|
WO2018114879A1
(en)
|
2016-12-21 |
2018-06-28 |
F. Hoffmann-La Roche Ag |
Method for in vitro glycoengineering of antibodies
|
CN110100007B
(zh)
|
2016-12-21 |
2024-05-28 |
豪夫迈·罗氏有限公司 |
用于体外糖工程化抗体的酶的再使用
|
AU2017384276B9
(en)
|
2016-12-21 |
2020-11-26 |
F. Hoffmann-La Roche Ag |
In vitro glycoengineering of antibodies
|
EP3559666A1
(en)
|
2016-12-21 |
2019-10-30 |
H. Hoffnabb-La Roche Ag |
Assay for determining antibody or ligand binding and function
|
WO2018115051A1
(en)
|
2016-12-22 |
2018-06-28 |
F. Hoffmann-La Roche Ag |
Treatment of tumors with an anti-csf-1r antibody in combination with an anti-pd-l1 antibody after failure of anti-pd-l1/pd1 treatment
|
JOP20190134A1
(ar)
|
2016-12-23 |
2019-06-02 |
Potenza Therapeutics Inc |
بروتينات رابطة لمولد ضد مضادة لنيوروبيلين وطرق استخدامها
|
WO2018122053A1
(en)
|
2016-12-29 |
2018-07-05 |
F. Hoffmann-La Roche Ag |
Anti-angiopoietin-2 antibody formulation
|
WO2018156785A1
(en)
|
2017-02-22 |
2018-08-30 |
Sutro Biopharma, Inc. |
Pd-1/tim-3 bi-specific antibodies, compositions thereof, and methods of making and using the same
|
CN110392697A
(zh)
|
2017-03-02 |
2019-10-29 |
国家医疗保健研究所 |
对nectin-4具有特异性的抗体及其用途
|
AU2018235092A1
(en)
|
2017-03-16 |
2019-08-15 |
Innate Pharma |
Compositions and methods for treating cancer
|
JOP20190203A1
(ar)
|
2017-03-30 |
2019-09-03 |
Potenza Therapeutics Inc |
بروتينات رابطة لمولد ضد مضادة لـ tigit وطرق استخدامها
|
EP3401332A1
(en)
|
2017-05-08 |
2018-11-14 |
MAB Discovery GmbH |
Anti-il-1r3 antibodies for use in inflammatory conditions
|
EP3630292A2
(en)
|
2017-05-24 |
2020-04-08 |
Sutro Biopharma, Inc. |
Pd-1/lag3 bi-specific antibodies, compositions thereof, and methods of making and using the same
|
WO2019018744A1
(en)
|
2017-07-21 |
2019-01-24 |
The United States Of America, As Represented By The Secretary, Department Of Health And Human Services |
IMMUNOGENIC COMPOSITIONS OF NEISSERIA MENINGITIDIS
|
WO2019020480A1
(en)
|
2017-07-24 |
2019-01-31 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
ANTIBODIES AND PEPTIDES FOR TREATING HCMV RELATED DISEASES
|
EP3658589B1
(en)
|
2017-07-26 |
2023-09-27 |
Forty Seven, Inc. |
Anti-sirp-alpha antibodies and related methods
|
WO2019020606A1
(en)
|
2017-07-26 |
2019-01-31 |
F. Hoffmann-La Roche Ag |
POLYTHERAPY WITH BET INHIBITOR, BCL-2 INHIBITOR AND ANTI-CD20 ANTIBODY
|
US20200207859A1
(en)
|
2017-07-26 |
2020-07-02 |
Sutro Biopharma, Inc. |
Methods of using anti-cd74 antibodies and antibody conjugates in treatment of t-cell lymphoma
|
WO2019055931A1
(en)
|
2017-09-18 |
2019-03-21 |
Sutro Biopharma, Inc. |
ALPHA ANTI-FOLATE ANTIBODY-RECEPTOR CONJUGATES AND USES THEREOF
|
JP7226833B2
(ja)
|
2017-09-21 |
2023-02-21 |
イムチェック セラピューティクス エスエーエス |
Btn2に特異性を有する抗体及びその使用
|
EP3694532A4
(en)
|
2017-10-10 |
2021-07-14 |
Gritstone Oncology, Inc. |
IDENTIFICATION OF NEOANTIGENS BY MEANS OF HOT SPOTS
|
US20200283537A1
(en)
|
2017-11-14 |
2020-09-10 |
University Of Virginia Patent Foundation |
Compositions and methods for making and using bispecific antibodies
|
JP2021503897A
(ja)
|
2017-11-22 |
2021-02-15 |
グリットストーン オンコロジー インコーポレイテッド |
新生抗原のためのジャンクションエピトープ提示の低減
|
GB201719646D0
(en)
|
2017-11-27 |
2018-01-10 |
Bivictrix Therapeutics Ltd |
Therapy
|
EP3728327A1
(en)
|
2017-12-22 |
2020-10-28 |
F. Hoffmann-La Roche AG |
Depletion of light chain mispaired antibody variants by hydrophobic interaction chromatography
|
CA3084370A1
(en)
|
2018-01-12 |
2019-07-18 |
Bristol-Myers Squibb Company |
Combination therapy with anti-il-8 antibodies and anti-pd-1 antibodies for treating cancer
|
CA3088355A1
(en)
|
2018-02-06 |
2019-08-15 |
F. Hoffmann-La Roche Ag |
Treatment of ophthalmologic diseases
|
EP3774901A1
(en)
|
2018-03-26 |
2021-02-17 |
Sutro Biopharma, Inc. |
Anti-bcma receptor antibodies, compositions comprising anti bcma receptor antibodies and methods of making and using anti-bcma antibodies
|
EP3774887A2
(en)
|
2018-03-28 |
2021-02-17 |
Axon Neuroscience SE |
Antibody-based methods of detecting and treating alzheimer's disease
|
CN112334485A
(zh)
|
2018-04-06 |
2021-02-05 |
百进生物科技公司 |
抗-四次穿膜蛋白33药剂及其组合物以及制备和使用方法
|
FI3774859T3
(fi)
|
2018-04-11 |
2024-05-24 |
Salubris Biotherapeutics Inc |
Ihmisen neureguliini-1:n (nrg-1) rekombinanttifuusioproteiinikoostumukset ja niiden käyttömenetelmät
|
GB201807367D0
(en)
|
2018-05-04 |
2018-06-20 |
Univ Newcastle |
Biomarker
|
WO2019231326A1
(en)
|
2018-05-31 |
2019-12-05 |
ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n.LUMC) |
Teipp neoantigens and uses thereof
|
CA3099893A1
(en)
|
2018-06-18 |
2019-12-26 |
Innate Pharma |
Compositions and methods for treating cancer
|
CN113614112A
(zh)
|
2018-09-10 |
2021-11-05 |
莱顿教学医院 |
MuSK抑制
|
EP3850015A1
(en)
|
2018-09-10 |
2021-07-21 |
Academisch Ziekenhuis Leiden h.o.d.n. LUMC |
Musk activation
|
WO2020060944A1
(en)
|
2018-09-17 |
2020-03-26 |
Sutro Biopharma, Inc. |
Combination therapies with anti-folate receptor antibody conjugates
|
WO2020068557A1
(en)
|
2018-09-25 |
2020-04-02 |
BioLegend, Inc. |
Anti-tlr9 agents and compositions and methods for making and using the same
|
WO2020069133A1
(en)
|
2018-09-27 |
2020-04-02 |
Tizona Therapeutics |
Anti-hla-g antibodies, compositions comprising anti-hla-g antibodies and methods of using anti-hla-g antibodies
|
GB201816554D0
(en)
|
2018-10-10 |
2018-11-28 |
Centauri Therapeutics Ltd |
Novel compounds and therapeutic uses thereof
|
GB201816553D0
(en)
|
2018-10-10 |
2018-11-28 |
Centauri Therapeutics Ltd |
Novel compounds and therapeutic uses thereof
|
EP3873519A1
(en)
|
2018-10-29 |
2021-09-08 |
F. Hoffmann-La Roche AG |
Antibody formulation
|
WO2020089437A1
(en)
|
2018-10-31 |
2020-05-07 |
Engmab Sàrl |
Combination therapy
|
WO2020094609A1
(en)
|
2018-11-06 |
2020-05-14 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Methods and pharmaceutical compositions for the treatment of acute myeloid leukemia by eradicating leukemic stem cells
|
AU2020222891A1
(en)
|
2019-02-11 |
2021-08-05 |
Zumutor Biologics Inc. |
Anti-CLEC2D antibodies and methods of use thereof
|
CA3134122A1
(en)
|
2019-03-20 |
2020-09-24 |
Imcheck Therapeutics Sas |
Antibodies having specificity for btn2 and uses thereof
|
WO2020193520A1
(en)
|
2019-03-25 |
2020-10-01 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
Treatment of taupathy disorders by targeting new tau species
|
SG11202112120WA
(en)
|
2019-05-03 |
2021-11-29 |
Celgene Corp |
Anti-bcma antibody conjugate, compositions comprising the same, and methods of making and using the same
|
WO2020227105A1
(en)
|
2019-05-03 |
2020-11-12 |
Sutro Biopharma, Inc. |
Anti-bcma antibody conjugates
|
CN114269749A
(zh)
|
2019-06-10 |
2022-04-01 |
苏特罗生物制药公司 |
5H-吡咯并[3,2-d]嘧啶-2,4-二氨基化合物及其抗体偶联物
|
WO2020257235A1
(en)
|
2019-06-17 |
2020-12-24 |
Sutro Biopharma, Inc. |
1-(4-(aminomethyl)benzyl)-2-butyl-2h-pyrazolo[3,4-c]quinolin-4-amine derivatives and related compounds as toll-like receptor (tlr) 7/8 agonists, as well as antibody drug conjugates thereof for use in cancer therapy and diagnosis
|
DE102019121007A1
(de)
|
2019-08-02 |
2021-02-04 |
Immatics Biotechnologies Gmbh |
Antigenbindende Proteine, die spezifisch an MAGE-A binden
|
US20210032370A1
(en)
|
2019-08-02 |
2021-02-04 |
Immatics Biotechnologies Gmbh |
Recruiting agent further binding an mhc molecule
|
JP2022543259A
(ja)
|
2019-08-02 |
2022-10-11 |
オレガ・バイオテック |
新規il-17b抗体
|
EP3825330A1
(en)
|
2019-11-19 |
2021-05-26 |
International-Drug-Development-Biotech |
Anti-cd117 antibodies and methods of use thereof
|
CN115427447A
(zh)
|
2020-01-17 |
2022-12-02 |
百进生物科技公司 |
抗tlr7药剂和组合物以及制备和使用其的方法
|
TW202200209A
(zh)
|
2020-02-28 |
2022-01-01 |
美商健臻公司 |
用於優化之藥物接合之經修飾的結合多肽
|
WO2021175954A1
(en)
|
2020-03-04 |
2021-09-10 |
Imcheck Therapeutics Sas |
Antibodies having specificity for btnl8 and uses thereof
|
JP2023522212A
(ja)
|
2020-04-17 |
2023-05-29 |
ニューヨーク・ユニバーシティ |
治療用musk抗体
|
EP4139340A1
(en)
|
2020-04-22 |
2023-03-01 |
Merck Sharp & Dohme LLC |
Human interleukin-2 conjugates biased for the interleukin-2 receptor beta gammac dimer and conjugated to a nonpeptidic, water-soluble polymer
|
US20230172923A1
(en)
|
2020-04-30 |
2023-06-08 |
Bristol-Myers Squibb Company |
Methods of treating cytokine-related adverse events
|
EP4149558A1
(en)
|
2020-05-12 |
2023-03-22 |
INSERM (Institut National de la Santé et de la Recherche Médicale) |
New method to treat cutaneous t-cell lymphomas and tfh derived lymphomas
|
EP3915641A1
(en)
|
2020-05-27 |
2021-12-01 |
International-Drug-Development-Biotech |
Anti-cd5 antibodies and methods of use thereof
|
WO2021252708A1
(en)
|
2020-06-11 |
2021-12-16 |
President And Fellows Of Harvard College |
Stabilized trioxacarcin antibody drug conjugates and uses thereof
|
EP4171742A1
(en)
|
2020-06-25 |
2023-05-03 |
MedImmune Limited |
Prevention of axonal damage using antibody binding to amyloid beta 1-42
|
US11484604B2
(en)
|
2020-08-07 |
2022-11-01 |
Fortis Therapeutics, Inc. |
Immunoconjugates targeting CD46 and methods of use thereof
|
CA3190586A1
(en)
|
2020-09-04 |
2022-03-10 |
Merck Patent Gmbh |
Anti-ceacam5 antibodies and conjugates and uses thereof
|
WO2022058700A1
(en)
|
2020-09-15 |
2022-03-24 |
Imperial College Innovations Limited |
Treatment of idiopathic pulmonary fibrosis
|
GB202016349D0
(en)
|
2020-10-15 |
2020-12-02 |
Imp College Innovations Ltd |
Proteome analysis in pulmonary hypertension
|
WO2022093640A1
(en)
|
2020-10-30 |
2022-05-05 |
BioLegend, Inc. |
Anti-nkg2c agents and compositions and methods for making and using the same
|
WO2022093641A1
(en)
|
2020-10-30 |
2022-05-05 |
BioLegend, Inc. |
Anti-nkg2a agents and compositions and methods for making and using the same
|
GB202017673D0
(en)
|
2020-11-09 |
2020-12-23 |
Imperial College Innovations Ltd |
Treatment of pulmonary arterial hypertensive
|
WO2022153212A1
(en)
|
2021-01-13 |
2022-07-21 |
Axon Neuroscience Se |
Antibodies neutralizing sars-cov-2
|
WO2022184805A1
(en)
|
2021-03-03 |
2022-09-09 |
Immatics Biotechnologies Gmbh |
Antigen binding proteins specifically binding sars-cov-2 antigenic peptides in complex with a major histocompatibility complex protein
|
KR20240004659A
(ko)
|
2021-04-30 |
2024-01-11 |
셀진 코포레이션 |
감마 세크레타제 억제제(gsi)와 병용하여 항-bcma 항체-약물 접합체(adc)를 사용하는 병용 요법
|
EP4340876A1
(en)
|
2021-05-19 |
2024-03-27 |
Sutro Biopharma, Inc. |
Anti-folate receptor conjugate combination therapy with bevacizumab
|
CA3226437A1
(en)
|
2021-07-27 |
2023-02-02 |
Sara Yousef |
Antigen binding proteins specifically binding ct45
|
CN118284623A
(zh)
|
2021-08-23 |
2024-07-02 |
伊莫尼塔斯治疗公司 |
抗cd161抗体及其用途
|
CA3234995A1
(en)
|
2021-10-14 |
2023-04-20 |
Latticon (Suzhou) Biopharmaceuticals Co., Ltd. |
Novel antibody-cytokine fusion protein, preparation method therefor and use thereof
|
TW202330613A
(zh)
|
2021-11-12 |
2023-08-01 |
美商建南德克公司 |
使用整聯蛋白β7拮抗劑治療克隆氏病之方法
|
WO2023096904A2
(en)
|
2021-11-24 |
2023-06-01 |
President And Fellows Of Harvard College |
C-16 modified trioxacarcins, antibody drug conjugates, and uses thereof
|
AU2022402850A1
(en)
|
2021-12-01 |
2024-06-06 |
Sutro Biopharma, Inc. |
Anti-folate receptor conjugate cancer therapy
|
AR128745A1
(es)
|
2022-03-09 |
2024-06-12 |
Merck Patent Gmbh |
Anticuerpos y conjugados anti-ceacam5 y usos de los mismos
|
WO2023169896A1
(en)
|
2022-03-09 |
2023-09-14 |
Astrazeneca Ab |
BINDING MOLECULES AGAINST FRα
|
WO2023170216A1
(en)
|
2022-03-11 |
2023-09-14 |
Astrazeneca Ab |
A SCORING METHOD FOR AN ANTI-FRα ANTIBODY-DRUG CONJUGATE THERAPY
|
TW202400217A
(zh)
|
2022-03-15 |
2024-01-01 |
美商信立泰生物醫藥公司 |
用神經調節蛋白-1融合蛋白治療纖維化及心律不整的方法
|
WO2024006563A1
(en)
|
2022-07-01 |
2024-01-04 |
Sutro Biopharma, Inc. |
Il-12 mutants with reduced toxicity, compositions thereof and methods of using the same
|
WO2024020051A1
(en)
|
2022-07-19 |
2024-01-25 |
BioLegend, Inc. |
Anti-cd157 antibodies, antigen-binding fragments thereof and compositions and methods for making and using the same
|
WO2024040114A2
(en)
|
2022-08-18 |
2024-02-22 |
BioLegend, Inc. |
Anti-axl antibodies, antigen-binding fragments thereof and methods for making and using the same
|
WO2024044780A1
(en)
|
2022-08-26 |
2024-02-29 |
Sutro Biopharma, Inc. |
Interleukin-18 variants and uses thereof
|
WO2024062074A1
(en)
|
2022-09-21 |
2024-03-28 |
Sanofi Biotechnology |
Humanized anti-il-1r3 antibody and methods of use
|
WO2024098023A2
(en)
|
2022-11-04 |
2024-05-10 |
Sutro Biopharma, Inc. |
Interferon alpha polypeptides and conjugates
|
WO2024136640A1
(en)
|
2022-12-21 |
2024-06-27 |
ACADEMISCH ZIEKENHUIS LEIDEN (h.o.d.n. LUMC) |
C1q antibodies and uses thereof
|